Navigation Links
Anavex advances drug candidate for treatment of Alzheimer's disease
Date:11/28/2007

Results from animal model testing demonstrate ANAVEX 1-41 has significant

neuroprotective and anti-amnesic benefits

GENEVA, Nov. 28 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.

The results are further highlighted in that this activity involves both muscarinic and sigma-1 receptor systems indicating a novel mechanism of action. Published results were presented at the Neuroscience 2007 conference in San Diego, California, and are available at http://www.anavex.com/publications.html. Testing on ANAVEX 1-41 is being conducted in cooperation with Universite Montpellier in France.

"The fact that we have evidence of neuroprotective action, which is essentially protection to any part of the body's nervous system, through the prevention of oxidative stress is a major milestone in the development of ANAVEX 1-41," said Dr. Vamvakides, Chief Scientific Officer of ANAVEX. "With this novel mechanism of action we anticipate that ANAVEX 1-41 may slow the progression of Alzheimer's disease and considerably improve the quality of life of those impacted by the disease as well as their caregivers."

The pre-clinical studies tested ANAVEX 1-41's ability to protect neurons, the nerve cells that make up the central nervous system, from degeneration or death. Testing was conducted in a non-transgenic mouse model of Alzheimer's dis
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
2. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. BioSpace Draws Over 600 Candidates to San Diego Life Science Career Fair
10. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Superdome and Denver,s Coors Field ... 17, and coincide with hemophilia community events in a dozen ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... 2015 Avelas Biosciences, an in vivo ... announced today that it has initiated a Phase 1b ... women with primary, non-recurrent breast cancer undergoing surgery. In ... addition of Steven Chen , M.D., as vice ... dose escalation study will enroll up to 39 women ...
(Date:4/16/2015)... April 16, 2015 Fairleigh Dickinson ... V. Gulfo to become the Executive Director of ... FDU announced the kick-off of the Initiative for ... by Dr. Gulfo, under the Rothman Institute of ... Business) and in collaboration with FDU’s School of ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... MADISON HEIGHTS, Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC ... ambulatory infusion pumps and associated clinical services,today announced ... the,third quarter ended September 30, 2008., Mr. ... pleased,to report a solid 14.5% increase in revenue ...
... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), announced today ... has retired at the close of business,October 31, 2008. ... leadership,team and a director for many years. The Company ... About AMDL:, Headquartered in Tustin, CA with ...
... from Same Prior Year Period, DUBLIN, Calif., Nov. ... company dedicated to the discovery and,development of novel cancer ... nine months ended September 30, 2008., Total revenues ... $6.1 million for the same prior year period. Total ...
Cached Biology Technology:InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11AMDL, Inc.'s President & CEO Mr. Gary Dreher Retires 2SuperGen Reports 2008 Third Quarter Financial Results 2SuperGen Reports 2008 Third Quarter Financial Results 3SuperGen Reports 2008 Third Quarter Financial Results 4SuperGen Reports 2008 Third Quarter Financial Results 5SuperGen Reports 2008 Third Quarter Financial Results 6SuperGen Reports 2008 Third Quarter Financial Results 7SuperGen Reports 2008 Third Quarter Financial Results 8SuperGen Reports 2008 Third Quarter Financial Results 9SuperGen Reports 2008 Third Quarter Financial Results 10
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... solar cells are expected to be highly efficient, thinner, more ... cells of today. This could pave the way for them ... globally. Nanyang Technological University (NTU) today announced that it ... set up a new research centre that will pioneer the ...
... co-authored by Columbia Engineering professor Kartik Chandran and recently ... , shows that reducing nitrogen pollution generated by wastewater ... well as the expected benefits for the environment. ... U.S. who worked on the study, along with James ...
... BELLINZONA (Switzerland) July 28, 2011 A paper ... , describes a novel, proprietary monoclonal antibody (FI6) discovered ... for Research in Biomedicine ("IRB") and the UK Medical ... that targets all 16 hemagglutinin subtypes of influenza A ...
Cached Biology News:NTU unveils new center to develop solar cells and clean energy systems of tomorrow 2NTU unveils new center to develop solar cells and clean energy systems of tomorrow 3New study outlines economic and environmental benefits to reducing nitrogen pollution 2New study outlines economic and environmental benefits to reducing nitrogen pollution 3Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A viruses 2
Special grade: for electrophoresis...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is ... the nucleus blue in color. ... excellent contrast to red fluorochromes ... Red, or R-Phycoerythrin. DAPI can ...
Contact us for more information...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: